RYTM did a 120% run in November and December and then pivoted to start the year. It competes in the anti-obesity drug space which is all the rage right now and has snack food manufactures freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382 retracement level and then pivoting into a reversal in the past week. The dual...
NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidation, NBIX appears poised for further growth, with technical...
Both biotech ETF's AMEX:XBI and NASDAQ:IBB are showing tremendous weakness in the face of a strong market. I suspect that when the market is ready to pullback it may take this a little lower especially in the face of a strong TVC:DXY / Dollar Index. Good luck traders!
Looking at the micro data, we have an uptrend where we're following along the rising bottom. Looking a bit further out, we can see we're in a bullish wedge. General trends say that this will come up, and the company will have only good news about their trials progressing which will drive the price higher. Very near to $2 by the end of February, and we could...
MGNX as a biotech company makes antibodies against certain cancers. The antibody is tagged to chemotherapy molecules and then heads off looking for cancer cells to which it has a strong affinity. So much for the science. MGNX just got upgraded and the new target is $ 16.00 about 25% upside. Biotech and healthcare are projected hot sectors this year. On the...
Can see this at $15.00 given that is where most shares are currently held, according to FRVP; this means there will likely be little downwards price pressure until then. Biotech is generally bearish outside of select, short-lived bull runs - this, in my opinion, creates an opportunity for sentiment arbitrage and is my reasoning for the trade (short term/long term...
IBB looks to be in a Wyckoff Redistribution phase, with UTAD emerging currently. On a larger time frame, looks as though a weekly H&S patter forming with the re-distribution section acting as the right shoulder. My price target is $57, in line with the 1.618 fib extension.
BLUE is currently trading above its 50-day and 200-day simple moving averages (SMA), indicating a bullish trend. However, the 50-day SMA is below the 200-day SMA, forming a death cross pattern, which is a bearish signal. The 20-day exponential moving average (EMA) is also above the current price, acting as a resistance level. A break above the 20-day EMA could...
According to the CEO of NVDA, the next big revolution is coming into biotech. Biology will be engineered and therefore will compound exponentially. Now might be a good time to enter this field.
If you haven`t bought SRPT here: Then you need to know that there is a Massive catalyst coming! Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November. This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17. Some...
Mostly sold out of all of my long positions. going to focus on shorts and puts. I am kicking myself, though, for Selling this one. Well, Live-long-and-Prosper, my friend....
Last year in Autumn we had this buyout rumor. I remember back then Exact Sciences said to approach Invitae about a potential merger. Now, NVTA, Invitae Corporation, is trading at an all-time low, $0.62. Some deals take one or two years to perfect, and we don't know what caused the recent price decrease. Sometimes this happens before an announcement. Today,...
GRI Bio recently underwent a 1/30 split on April 24th, accompanied by a merger/restructure of Vallon Pharmaceuticals. The stock price immediately tanked approx. 50% in the following days. The price has held above the low of $5.50 on April 26th for over a month. Based on past performance, this stock has a tendency to jump 30 to >200% in a single day. GRI Bio has...
ETON jumped on a big earnings report a week ago. This small cap biotechology company is making big money and traders responded. It has now experienced a standard 0.5 Fib level retracement pullback and traders early in the jump take profit. At this level new buyers have equilibrated with those selling their shares and taking profit. The ZL MACD lines are...
If you haven`t bought the Double Bottom on QSI: Then it seems that there is a potential reversal from this level. Earnings were a beat, but too small to justify the recent breakout. The Elliot Waves chart pattern indicates a price target of $2.93. Looking forward to read your opinion about it!
NKTR is due for earnings on August 8th. The price from the opening bell on the 7th pump nearly 100% to over $1.00 and then faded by a couple of cents. The Price Momentum Oscillator and ZL MACD indicators tracked the high velocity action into a high tight type bull falg which is often considered to be predictive of another leg up of similar magnitude. I will be...
If you haven`t bought the Double Bottom: Then you should know that QSI, Quantum-Si incorporated, also known as The Protein Sequencing Company is bringing single-molecule protein sequencing to every lab, everywhere, enabling new discoveries that will transform the world we live in. Importance of Protein Sequencing: - Understanding Cellular Processes: Proteins...